Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Laropiprant (MK-0524) is a potent and selective antagonist of prostaglandin D2 (PGD2) receptor (DP) such as and DP/DP1 receptor(Ki = 0.57 nM) and TP Receptor(Ki = 2.95 nM).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 54.00 | |
2 mg | In stock | $ 78.00 | |
5 mg | In stock | $ 132.00 | |
10 mg | In stock | $ 192.00 | |
25 mg | In stock | $ 385.00 | |
50 mg | In stock | $ 592.00 | |
100 mg | In stock | $ 845.00 | |
500 mg | In stock | $ 1,690.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 145.00 |
Description | Laropiprant (MK-0524) is a potent and selective antagonist of prostaglandin D2 (PGD2) receptor (DP) such as and DP/DP1 receptor(Ki = 0.57 nM) and TP Receptor(Ki = 2.95 nM). |
Targets&IC50 | DP/DP1 receptor:0.57 nM (ki), TP receptor:2.95 nM (ki) |
In vitro | Laropiprant blocks DP receptor-dependent enhance in VASP phosphorylation, as well as inhibition of P-selectin expression, GPIIb/IIIa activation, and in vitro thrombus formation. Laropiprant antagonizes the increased platelet aggregation by TP and EP3 receptor activation. Laropiprant (1 μM) induces a significant inhibition of the aggregation but still counteracts the pronounced inhibition caused by PGD2 (30 nM) and BW245c (3 nM). Laropiprant (10 μM) and niacin inhibit in vitro thrombus formation[2]. |
Synonyms | MK-0524 |
Molecular Weight | 435.9 |
Formula | C21H19ClFNO4S |
CAS No. | 571170-77-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 100 mg/mL (229.41 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Laropiprant 571170-77-9 GPCR/G Protein Immunology/Inflammation Prostaglandin Receptor DP receptor inhibit metabolismacyl MK0524 MK-0524 Inhibitor MK 0524 pharmacokinetics glucuronide inhibitor